Testing effectiveness (Phase 2)Study completedNCT04291781
What this trial is testing
RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
Who this might be right for
Primary IgA Nephropathy
RemeGen Co., Ltd. 44